Pacylex News has migrated to Newsroom. Click the link below to access the latest articles and press releases.
Pacylex today announced that data from the first ever clinical trial of an N-myristoyltransferase (NMT) inhibitor was presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021. This update included the design of the first clinical trial with PCLX-001 in Non-Hodgkin’s Lymphoma and solid tumor patients and an update on the first dose cohort.
Read the full press release here: Pacylex ASH Annual Meeting Poster.